Affordable Access

Publisher Website

AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Authors
Type
Published Article
Journal
Psychopharmacology
Publication Date
Volume
215
Issue
1
Pages
149–163
Identifiers
DOI: 10.1007/s00213-010-2124-0
PMID: 21181124
Source
Medline

Abstract

These preclinical data suggest that AVE1625 may be useful to treat the cognitive deficits in schizophrenia and as a co-treatment with currently available antipsychotics. In addition, an improved side-effect profile was seen, with potential to ameliorate the EPS and weight gain issues with currently available treatments.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments